Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 44 Published: December 30, 2021 Report Code: GMDGDHC3046TDB

The Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) Drugs in Development market research report provides in-depth analysis of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted pipeline therapeutics. The report provides comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the mechanisms of action of the Metabotropic Glutamate Receptor 4 pipeline drugs market?

The mechanisms of action of the Metabotropic Glutamate Receptor 4 pipeline drugs market are Metabotropic Glutamate Receptor 4 Agonist and Metabotropic Glutamate Receptor 4 Antagonist.

Metabotropic Glutamate Receptor 4 pipeline drugs market, by mechanisms of action

Metabotropic Glutamate Receptor 4 pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Metabotropic Glutamate Receptor 4 pipeline drugs market?

The routes of administration in the Metabotropic Glutamate Receptor 4 pipeline drugs market are oral and intravenous.

Metabotropic Glutamate Receptor 4 pipeline drugs market, by routes of administration

Metabotropic Glutamate Receptor 4 pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What is the key molecule type in the Metabotropic Glutamate Receptor 4 pipeline drugs market?

The key molecule type in the Metabotropic Glutamate Receptor 4 pipeline drugs market is small molecule.

Which are the key companies in the Metabotropic Glutamate Receptor 4 pipeline drugs market?

The key companies in the Metabotropic Glutamate Receptor 4 pipeline drugs market are Addex Therapeutics Ltd, Appello Pharmaceuticals Inc, Bio-Pharm Solutions Co Ltd, Bristol-Myers Squibb Co, Domain Therapeutics SA, and H. Lundbeck AS.

Metabotropic Glutamate Receptor 4 pipeline drugs market, by key companies

Metabotropic Glutamate Receptor 4 pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Mechanisms of Action Metabotropic Glutamate Receptor 4 Agonist and Metabotropic Glutamate Receptor 4 Antagonist
Routes of Administration Oral and Intravenous
Molecule Types Small Molecule
Key Companies Addex Therapeutics Ltd, Appello Pharmaceuticals Inc, Bio-Pharm Solutions Co Ltd, Bristol-Myers Squibb Co, Domain Therapeutics SA, and H. Lundbeck AS

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4).
  • Reviews of pipeline therapeutics for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) therapeutics and enlists all their major and minor projects.
  • Assessment of Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

Addex Therapeutics Ltd

Appello Pharmaceuticals Inc

Bio-Pharm Solutions Co Ltd

Bristol-Myers Squibb Co

Domain Therapeutics SA

H. Lundbeck AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Overview

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Companies Involved in Therapeutics Development

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Drug Profiles

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Dormant Products

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Discontinued Products

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Addex Therapeutics Ltd, 2021

Pipeline by Appello Pharmaceuticals Inc, 2021

Pipeline by Bio-Pharm Solutions Co Ltd, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Domain Therapeutics SA, 2021

Pipeline by H. Lundbeck AS, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.